AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04439032 — intervention group
Intervention type: OTHER
Intervention: NanoBone Bone Graft Substitute
Description: Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
Study NCT01583972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: retinyl palmitate
Description: 50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule
Study NCT01583972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
Study NCT03422120 — intervention group
Intervention type: OTHER
Intervention: Natural Killer Cell Activity Assay
Description: Subjects had a blood test to measure NK cell activity (NKA) at different time points
Study NCT02253810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Medication administered intra-operatively to promote blood clotting.
Study NCT02253810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study NCT03199027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence Club
Description: Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.
Study NCT01707056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coffee with Milk
Description: Taking Synthroid with 12 ounces of black coffee and 2 ounces of 2% milk for a period of 6 weeks.
Study NCT01707056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black Tea
Description: Taking Synthroid with 12 ounces of black tea for a period of 6 weeks.
Study NCT01707056 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Taking Synthroid with water for a period of 6 weeks.
Study NCT05606783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Follow-up Visits
Description: • Follow-up with patients once per week for six (6) weeks via scheduled 20-minute telehealth appointment with each patient via the HIPAA secure and compliant platform, VSee~o During this telehealth appointment, the study pharmacists will counsel the patients on their blood pressure readings for that week and provide lifestyle education focusing on patient-specific diet and exercise recommendations
Study NCT03322228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy is tailored to subject preference. Examples are active music-making, supportive listening, and includes opportunities for legacy building to decrease caregiver distress and promote self-care.
Study NCT03037528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.
Study NCT03037528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive affect informational materials
Description: Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.
Study NCT01647204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trained volunteer mealtime assistance
Description: trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
Study NCT04950452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Supervised exercise training
Study NCT03142464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension of the IV fluids
Description: No IV fluids prescription, IV catheter filled with saline solution
Study NCT03927209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: tablet
Study NCT02096601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD/CD SC solution
Description: Levodopa/carbidopa SC solution
Study NCT05606783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys
Description: A pre- and post-survey will be given at the initial and final in-person appointments, respectively~• These surveys will collect basic patient demographics, knowledge of blood pressure, comfort with checking blood pressure at home, and previous experience working with a pharmacist
Study NCT05606783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Devices
Description: Smart Phones with Apple Health Software will be used to monitor blood pressure once a day, and results will be sent automatically to the patients EHR (Epic)~• The Omron 10 Series Wireless Upper Arm Blood Pressure Device will be given to the patient to monitor blood pressure at home daily
Study NCT03544723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-p53
Description: Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors. Immunotherapy. Gene Therapy.
Study NCT01231893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: olfactory mucosa ensheathing cell grafting, rehabilitation
Description: In this group patients are planned to underwent a biopsy of their own olfactory mucosa for isolation and culture of olfactory ensheathing cells and olfactory fibroblasts. The suspension of these cells will be next transplanted into the focus of spinal cord injury. Before and after surgery the patients will undergo an intense neurorehabilitation program.
Study NCT01231893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: In this group the patients will not undergo any surgical procedure. They will participate in the same rehabilitation protocol that is planned for the patients from the experimental group.
Study NCT02096601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone
Description: Entacapone 200 mg oral tablet
Study NCT01802021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astagalus-based Formula: Qingshu-Yiqi-Tang
Description: Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.~maximal for 6 months
Study NCT00137501 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nifedipine
Description: Arm A:~Nifedipine 20 mg sublingual, repeated after 30 minutes if contractions do not decrease in intensity. Maintenance of 120-160 mgs of slow-release nifedipine daily for 48 hours.Once contractions cease, nifedipine will be maintained at 80-120 mg daily in divided doses up to 36 weeks.~Arm B:~Nifedipine 10 mg sublingual crushed, then 10 mg in 15 min, followed by 10 mg PO Q 15 mins PRN to a maximum of 40 mg in the first hour. Maintenance of 60-80 mgs of slow-release nifedipine daily for 48 hours. Once contractions cease, nifedipine will be maintained at 60 mg daily in divided doses up to 36 weeks.
Study NCT02159313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat(Adempas,BAY63-2521)
Description: Single dose of a whole 2.5 mg riociguat tablet
Study NCT01276041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab in combination with trastuzumab and paclitaxel
Description: The regimen will consist of paclitaxel (80 mg/m2) weekly + trastuzumab every 3 weeks (8 mg/kg loading dose → 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose → 420 mg), all given intravenously (IV). Patients may be given trastuzumab weekly in lieu of every 3 weeks (4 mg/kg loading dose → 2 mg/kg every 3 weeks). Patients will be on treatment until progression of disease.
Study NCT02897024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
Study NCT02897024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
Study NCT02387840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses.
Study NCT02387840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Fingerprinting
Description: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2).
Study NCT02286843 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 89Zr-trastuzumab
Study NCT02286843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Study NCT02286843 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 89Zr-pertuzumab
Study NCT01397357 — intervention group
Intervention type: OTHER
Intervention: Cardiac magnetic resonance - CINE MRI stress test.
Description: Cardiac magnetic resonance - dipyridamole or dobutamine MRI stress test.
Study NCT04844112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: automatic CT/MRI-US fusion system guided radiofrequency ablation
Description: automatic CT/MRI-US fusion system guided radiofrequency ablation
Study NCT00631215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy: 1.3 atmospheres of pressure, 100%0xygen by face mask, for 60 minutes
Study NCT03701893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus PS11610
Description: 7 months and a half intervention study. A 6 months intervention period preceded by a period of sampling and analysis of vaginal, seminal and gland swabs of 6 weeks. During the 6 months of intervention the men participants will intake one capsule that contains 1\*10E9 colony forming unit (CFU) of Lactobacillus PS11610 and the women participating will intake two capsules of the same product (each 12 hours). If the couple stay pregnant during the intervention the man will end the product intake and the woman will reduce the dose to one capsule with 1\*10E9 CFU of Lactobacillus PS11610 per day during 12 additional weeks.
Study NCT03754010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Under local anesthesia, full-mouth SRP will be performed by a single investigator. Immediately after the SRP, HA gel or mouthrinse will perform according to the groups' procedure. In Group 1, the periodontal sulcus will be irrigated with saline solution after SRP.
Study NCT03754010 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planning
Description: Under local anesthesia, full-mouth SRP will be performed by a single investigator. Immediately after the SRP, HA gel or mouthrinse will perform according to the groups' procedure. In Group 1, the periodontal sulcus will be irrigated with saline solution after SRP.
Study NCT03754010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (HA) and SRP
Description: In Group 2, after SRP will be performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA will be applied intrasulcular.
Study NCT03754010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA mouthrinse and SRP
Description: In Group 3, HA hydrogel mouthrinse will be used as an irrigator after SRP.
Study NCT03754010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA mouthrinse+gel and SRP
Description: In Group 4, after SRP will be performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel will be applied.
Study NCT03423797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% AgNO3 solution followed by 5% NaF
Description: Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF: 11.6mg (F-)/0.5ml (max dose).
Study NCT03423797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% AgNO3 solution followed by 5% NaF with fTCP
Description: Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF with fTCP: 11.6mg (F-)/0.5ml (max dose).
Study NCT01486225 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Innothera's brand Stockings
Description: 15 patients having used Innothera branded Stocking
Study NCT01486225 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stockings other than Innothera's brand
Description: 15 patients having used any other brand than Innothera's brand stockings
Study NCT01791309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination panitumumab and vemurafenib
Description: Treatment will consist of panitumumab 6mg/kg IV every 14 days and vemurafenib 960mg orally twice daily. In patients who initially respond to treatment and later progress, a voluntary biopsy will be requested at the time of relapse to study mechanisms of acquired resistance. This biopsy should consist of at least one frozen core specimen. Every effort will be made to obtain this biopsy within 30 days of discontinuation of treatment and before the initiation of any new tumor-directed therapies.
Study NCT00725920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: patients will receive the active drug. The starting dose was 25 mg/day, with weekly increments of 25 mg/day, according to clinical status. The maximum dose considered was 200 mg/day
Study NCT00725920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control group
Description: initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day
Study NCT00725920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo control group
Description: initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day
Study NCT04215887 — intervention group
Intervention type: DEVICE
Intervention: Contactless Portable Respiratory rate Monitor
Description: Novel hand-held respiratory rate monitor
Study NCT04245254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Protien Powder
Description: Collegen Protein Powser
Study NCT02244281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Study NCT02244281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01687894 — intervention group
Intervention type: DRUG
Intervention: Vasopressins
Description: Vasopressins propofol vasopressins sevoflurane
Study NCT01687894 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Placebo propofol \& placebo sevoflurane
Study NCT03037528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness informational materials
Description: Participants will be taught about mindfulness and mindful eating techniques.
Study NCT03037528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary tracking
Description: Participants will be asked to track their diet consistently.
Study NCT00605046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT scan
Description: AV151-01: Evaluation of \[123I\] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
Study NCT01467999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine, 4mg given once daily
Study NCT02787473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed 500mg/m2 IV on day 1 every 4 weeks for 2 cycles
Study NCT02787473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin 25mg/m2 IV on day 1-3 every 4 weeks for 2 cycles
Study NCT02787473 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiation therapy
Description: Chemoradiotherapy, radiation 60Gy with 2 cycles of pemetrexed+ carboplatin/cisplatin
Study NCT02787473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel 60 mg/m2 IV on day 57 every 3 weeks for 2 cycles
Study NCT04468932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Aim 1: To determine the clinical effects of rTMS targeting the cerebellum on postural instability in PSP. The hypothesis to be tested is that TMS augmentation of cerebellar inhibition will improve cerebellum-dependent balance symptoms of PSP for a period of time sufficient to improve rehabilitation outcomes. The investigators will measure a battery of objective posturography metrics and other measures of motor control, including sway and center of pressure changes to backward tilt and forward translation.~Aim 2: We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS. The hypothesis to be tested is that premotor and motor cortical activity will decrease after cerebellar rTMS compared to sham TMS, reflecting improved cerebellar inhibition of the motor cortex after the intervention.
Study NCT03794037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dydrgesterone 10 mg( tab)/12hs/14 days
Description: Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
Study NCT03794037 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
Description: montelukast 10 mg(tab) once daily oral for 7 days \& dydrgesterone 10 mg (tab) twice daily oral for 14 days \&
Study NCT03499392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: psychological tests
Description: psychological tests psychological interviews
Study NCT01889316 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Novii
Description: The Novii is a modified device with similar technology to the AN24 device already being used in the USA.
Study NCT01889316 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AN24
Study NCT03951922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horticultural activity
Description: Therapeutic horticulture activities are plant-related activities that include but not limited to digging, watering, planting, weeding, trimming, fertilizing, mulching, harvesting, learning about organic farming, and exploring options to incorporate horticulture into daily activities
Study NCT01687894 — intervention group
Intervention type: DRUG
Intervention: propofol
Description: vasopressin propofol \& placebo propofol
Study NCT03748199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6014
Description: DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)
Study NCT03748199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally at a dose and frequency matched to POL6014
Study NCT01162382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
Study NCT00882258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg Proellex
Description: 12.5 mg Proellex administered orally daily
Study NCT00882258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Proellex
Description: 25 mg Proellex administered orally daily
Study NCT00882258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally daily